Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics ...

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Opinion - This past weekend, I had the joy of escaping the city for a stay at the breathtaking Cleo Hotel, nestled along the shores of Lake Kivu, in western Rwanda. The journey from Kigali to Lake ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.